ClinicalTrials.gg
CompletedNCT02224664Updated Mar 27, 2017Results posted

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease

A Phase 1 interventional study of PF-06649751 and PF-06649751 in Parkinson's Disease, sponsored by Pfizer. Completed at 17 sites in 2 countries. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-03-27.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
30 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing tavapadon in Parkinson Disease — none open to participants now, none under way, none of them phase 3. tavapadon · Parkinson Disease.

Enrollment
7th of 11
50 · median 57
Started
2014
the only one that year
Phase 1
5 of 11
none open now
Registered
1st of 11
by date
Lead sponsor
4 of 11
Pfizer

Among the 11 studies testing tavapadon in Parkinson Disease, this one is the 7th largest by enrollment, is the only one that started in 2014, is one of 5 in phase 1, and was the 1st registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 11 studies testing tavapadon in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About tavapadon

tavapadon: first FDA approval 2026 (JUVMO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing tavapadon in Parkinson Disease as a file.
02

Study summary

This study will be an open label, dose escalation study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated daily quaque die (QD) doses given over 21 days (Day 3 to Day 23) to sequential cohorts of subjects with Parkinson's disease. Each cohort will have 2 study periods. For each cohort, subjects will enter Period 1 and if they meet criteria, approximately 12 subjects will be enrolled into Period 2 and dosed with PF 06649751. Based on results observed in a previous study, Cohorts 1 and 2 will not be conducted. Cohorts 3 - 6 will test doses uptitrated to 5 mg, 15 mg and 25 mg QD. Doses may be modified based on emerging safety, tolerability and PK data, but the maximum daily dose that will be given in any cohort will have PK predictions at steady state that are anticipated to be below toxicokinetic limits. An option for down titration to the previous dose level is available should the investigator consider that an AE is intolerable. Following down titration, a single up titration to the next dose level may be attempted if the subject remains symptom free for at least 48 hrs. Safety, tolerability and PK data of Cohort 3 will be reviewed prior to initiating the dosing in Cohorts 4 and 5. Available safety, tolerability and PK data up to Day 24 of at least 5 subjects from Cohorts 4 will be reviewed prior to initiating the dosing in Cohort 6.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of idiopathic Parkinson's Disease with at least 2 out of 3 cardinal characteristics (tremor, rigidity, bradykinesia)
  • (MMSE) ≥ 25
  • Hoehn \& Yahr Stage I-III inclusive
  • Documented history of end of L-Dopa wearing OFF
  • Cohort 5 only: History of dyskinesia following L-Dopa dosing and Score of at least 2 on Part IV, item 4.2 (functional impact of dyskinesia) of the MDS-UPDRS

Exclusion criteria

Exclusion Criteria:

  • Atypical/secondary parkinsonism
  • History of surgical intervention for Parkinson's Disease
  • Dementia/cognitive impairment that can interfere with study assessments
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Cohort 3

    Titration of PF-06649751 up to 5 mg QD

    Drug: PF-06649751

  • Experimental
    Cohort 4

    Titration of PF-06649751 up to 15 mg QD

    Drug: PF-06649751

  • Experimental
    Cohort 5

    Titration of PF-06649751 up to 15 mg QDi n subjects with Levodopa-induced dyskinesias (LID)

    Drug: PF-06649751

  • Experimental
    Cohort 6

    Titration of PF-0649751 up to 25 mg QD

    Drug: PF-06649751

Interventions

  • Oral daily doses titrated up to 5mg QD

  • Oral daily doses titrated up to 15 mg QD

  • Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)

  • Oral daily doses titrated up to 25 mg QD

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug to the end of study (up to Day 30) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.

    Time frame: Baseline (Day 1) up to Day 30

  2. Number of Participants With Laboratory Test Abnormalities

    Criteria for laboratory abnormalities: Hemoglobin (Hgb),hematocrit, red blood cell(RBC) count: less than(\<)0.8\*lower limit of normal(LLN),mean corpuscular Hgb, mean corpuscular volume, mean corpuscular Hgb concentration:\<0.9\*LLN, greater than (\>)1.1\*upper limit of normal(ULN),platelet:\<0.5\*LLN,\>1.75\*ULN,lymphocyte,neutrophil:\<0.8\*LLN, \>1.2\*ULN, basophil, eosinophil, monocyte:\>1.2\*ULN, WBC:\<0.6\*LLN, \>1.5\*ULN;total bilirubin\>1.5\*ULN, aspartate aminotransferase,alanine aminotransferase,alkaline phosphatase:\>3.0\*ULN,total protein,albumin:\<0.8\*LLN,\>1.2\*ULN;blood urea nitrogen,creatinine:\>1.3\*ULN, uric acid\>1.2\*ULN;sodium\<0.95\*LLN,\>1.05\*ULN,potassium,chloride,calcium,bicarbonate:\<0.9\*LLN,\>1.1\*ULN;glucose\<0.6\*LLN,\>1.5\*ULN,urine pH:\<4.5, \>8; urine: WBC, RBC greater than or equal to (\>=)20/high performance field, bacteria: \>20; urobilinogen, urine: glucose, ketone, protein, Hgb, nitrite, leukocyte esterase, bilirubin: \>=1.

    Time frame: Baseline up to Day 30

  3. Number of Participants With Vital Sign Abnormalities

    Criteria for vital sign abnormality included supine pulse rate of \<40 beats per minute (bpm) or \>120 bpm, standing pulse rate of \<40 bpm or \>140 bpm, supine and standing systolic blood pressure (SBP) \<90 millimeter of mercury (mmHg), supine and standing diastolic blood pressure (DBP) \<50 mmHg, supine and standing SBP of \>=30 mmHg maximum (max.) increase from baseline (IFB) and and decrease from baseline (DFB) in same posture, supine and Standing DBP of \>=20 mmHg max. increase and decrease from baseline in same posture. Categories in which there was atleast 1 abnormality are reported in this outcome measure.

    Time frame: Baseline up to Day 30

  4. Number of Participants With Electrocardiogram (ECG) Abnormalities

    Criteria for ECG abnormalities: maximum PR interval \>=300 milliseconds (msec) and maximum increase PR interval increase from baseline (IFB): percent change (Pctchg) \>=25 percent (%) for baseline value of \>200 msec and Pctchg\>=50% for baseline value of \<=200 msec for PR interval, maximum QRS interval \>=140 msec and a maximum IFB: Pctchg\>=50%, maximum QTCF interval (Fridericia's Correction) of 450 msec to \<480 msec, 480 msec to \<500 msec or \>=500 msec and a maximum change of \<=30change\<60 or \>=60 msec from baseline.

    Time frame: Baseline up to Day 30

  5. Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings

    Physical examination included examination of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision.

    Time frame: Baseline up to Day 30

  6. Number of Participants With Clinically Significant Neurological Examination Abnormality

    The complete or full neurological examination included assessment of the cranial nerves; muscle strength, tone, cortical drift, abnormal movements; deep tendon reflexes; sensory exam, coordination, gait and station. Higher cortical and motor function was considered part of the complete neurological exam. Findings were considered abnormal as confirmed by a certified neurologist.

    Time frame: Baseline up to Day 30

  7. Number of Participants With Categorical Scores on The Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").

    Time frame: Baseline up to Day 30

  8. Change From Baseline in Parkinson's Disease Diary For Participants With Motor Fluctuations at Day 13

    According to Parkinson's disease diaries of participants "OFF" time was a time period when the medication no longer providing benefit with regard to mobility, slowness, and stiffness and participants experienced relatively poor overall function with worsening of tremor, rigidity, balance, or bradykinesia. "ON" time was a time period when medication was providing benefit with regard to mobility, slowness, and stiffness. "ON" time was classified as associated with or without troublesome dyskinesia (TD) that interfere with activities of daily living and with or without dyskinesia. "OFF" time and "ON" time with TD were generally considered to be "bad time" with regard to motor function, whereas "ON" time without dyskinesia (WD) and with non- troublesome dyskinesia (NTD) were generally considered to be "good time".

    Time frame: Baseline, Day 13

  9. Change From Baseline in Parkinson's Disease Diary For Participants With Motor Fluctuations at Day 20

    According to Parkinson's disease diaries of participants "OFF" time was a time period when the medication no longer providing benefit with regard to mobility, slowness, and stiffness and participants experienced relatively poor overall function with worsening of tremor, rigidity, balance, or bradykinesia. "ON" time was a time period when medication was providing benefit with regard to mobility, slowness, and stiffness. "ON" time was classified as associated with or without troublesome dyskinesia (TD) that interfere with activities of daily living and with or without dyskinesia. "OFF" time and "ON" time with TD were generally considered to be "bad time" with regard to motor function, whereas "ON" time without dyskinesia (WD) and with non- troublesome dyskinesia (NTD) were generally considered to be "good time".

    Time frame: Baseline, Day 20

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of L-Dopa

    Time frame: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax) of L-Dopa

    Time frame: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1

  3. Apparent Clearance (CL/F) of L-Dopa

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1

  4. Terminal Half-Life (t1/2) of L-Dopa

    Terminal half-life is the time measured for the plasma concentration of drug to decrease by one half. It was calculated as dividing the natural logarithm to the base e (Log e)\*2/k el, where k el is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1

  5. Area Under the Curve From Time Zero Extrapolated to Infinite Time of L-Dopa

    AUC (0 - inf)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from AUC (0 - t) plus AUC (t - inf).

    Time frame: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1

  6. Area Under the Curve From Time Zero to Last Quantifiable Concentration of L-Dopa

    Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (C last).

    Time frame: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1

  7. Apparent Volume of Distribution (Vz/F) of L-Dopa

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1

  8. Maximum Observed Plasma Concentration (Cmax) of PF-06649751

    Time frame: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22

  9. Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06649751

    Time frame: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22

  10. Apparent Clearance (CL/F) of PF-06649751

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 22

  11. Area Under the Curve From Time Zero to End of Dosing Interval of PF-06649751

    Area under the concentration curve from time zero to end of dosing interval (AUCtau), where dosing interval was 12 hours.

    Time frame: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22

  12. Minimum Observed Plasma Trough Concentration (Cmin) of PF-06649751

    Time frame: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22

  13. Ratio of Accumulation for Area Under the Curve From Time Zero to End of Dosing Interval of PF-06649751

    Rac was obtained from AUCtau after last dose divided by AUCtau after first dose, where AUC(tau) = Area under the concentration curve from time zero to end of dosing interval (AUCtau), where dosing interval was 12 hours.

    Time frame: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22

07

Results

Posted Mar 27, 2017

Participant flow

Lead-in Period (3 Days)
Participant flow — Lead-in Period (3 Days)
MilestoneL-DopaPF-06649751 5 mg + L-DopaPF-06649751 15 mg + L-DopaPF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID)PF-06649751 25 mg + L-Dopa
Started500000
Completed450000
Not completed50000
Withdrew: Does not meet entrance criteria50000
Dose Escalation Period (21 Days)
Participant flow — Dose Escalation Period (21 Days)
MilestoneL-DopaPF-06649751 5 mg + L-DopaPF-06649751 15 mg + L-DopaPF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID)PF-06649751 25 mg + L-Dopa
Started0911619
Completed09938
Not completed002311
Withdrew: Adverse event00227
Withdrew: Withdrawal by subject00014

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug to the end of study (up to Day 30) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.

Time frame:
Baseline (Day 1) up to Day 30
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsL-DopaPF-06649751 5 mg + L-DopaPF-06649751 15 mg + L-DopaPF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID)PF-06649751 25 mg + L-Dopa
AEs997515
SAEs00001
PrimaryNumber of Participants With Laboratory Test Abnormalities

Criteria for laboratory abnormalities: Hemoglobin (Hgb),hematocrit, red blood cell(RBC) count: less than(\<)0.8\*lower limit of normal(LLN),mean corpuscular Hgb, mean corpuscular volume, mean corpuscular Hgb concentration:\<0.9\*LLN, greater than (\>)1.1\*upper limit of normal(ULN),platelet:\<0.5\*LLN,\>1.75\*ULN,lymphocyte,neutrophil:\<0.8\*LLN, \>1.2\*ULN, basophil, eosinophil, monocyte:\>1.2\*ULN, WBC:\<0.6\*LLN, \>1.5\*ULN;total bilirubin\>1.5\*ULN, aspartate aminotransferase,alanine aminotransferase,alkaline phosphatase:\>3.0\*ULN,total protein,albumin:\<0.8\*LLN,\>1.2\*ULN;blood urea nitrogen,creatinine:\>1.3\*ULN, uric acid\>1.2\*ULN;sodium\<0.95\*LLN,\>1.05\*ULN,potassium,chloride,calcium,bicarbonate:\<0.9\*LLN,\>1.1\*ULN;glucose\<0.6\*LLN,\>1.5\*ULN,urine pH:\<4.5, \>8; urine: WBC, RBC greater than or equal to (\>=)20/high performance field, bacteria: \>20; urobilinogen, urine: glucose, ketone, protein, Hgb, nitrite, leukocyte esterase, bilirubin: \>=1.

Time frame:
Baseline up to Day 30
Reported as:
Number · participants
Number of Participants With Laboratory Test Abnormalities
participantsL-DopaPF-06649751 5 mg + L-DopaPF-06649751 15 mg + L-DopaPF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID)PF-06649751 25 mg + L-Dopa
Number of Participants With Laboratory Test Abnormalities1788511
PrimaryNumber of Participants With Vital Sign Abnormalities

Criteria for vital sign abnormality included supine pulse rate of \<40 beats per minute (bpm) or \>120 bpm, standing pulse rate of \<40 bpm or \>140 bpm, supine and standing systolic blood pressure (SBP) \<90 millimeter of mercury (mmHg), supine and standing diastolic blood pressure (DBP) \<50 mmHg, supine and standing SBP of \>=30 mmHg maximum (max.) increase from baseline (IFB) and and decrease from baseline (DFB) in same posture, supine and Standing DBP of \>=20 mmHg max. increase and decrease from baseline in same posture. Categories in which there was atleast 1 abnormality are reported in this outcome measure.

Time frame:
Baseline up to Day 30
Reported as:
Number · participants
Number of Participants With Vital Sign Abnormalities
participantsL-DopaPF-06649751 5 mg + L-DopaPF-06649751 15 mg + L-DopaPF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID)PF-06649751 25 mg + L-Dopa
Supine SBP: <90 mmHg (n =50, 9, 11, 6, 19)21111
Standing SBP: <90 mmHg (n =50, 9, 11, 6, 19)52310
Supine DBP: <50 mmHg (n =50, 9, 11, 6, 19)11001
Max. IFB in Supine SBP: >=30 mmHg (n=50,9,11,6,19)12102
Max. IFB in StandingSBP:>=30 mmHg(n= 49,9,11,6,19)31002
Max. IFB in Supine DBP: >=20 mmHg(n= 50,9,11,6,19)11201
Max. IFB in StandingDBP:>=20 mmHg(n= 49,9,11,6,19)10002
Max. DFB in Supine SBP:>=30 mmHg (n= 50,9,11,6,19)81315
Max. DFB in StandingSBP:>=30 mmHg(n= 49,9,11,6,19)72424
Max. DFB in Supine DBP:>=20 mmHg (n= 50,9,11,6,19)93238
Max. DFB in StandingDBP:>=20 mmHg(n= 49,9,11,6,19)112325
PrimaryNumber of Participants With Electrocardiogram (ECG) Abnormalities

Criteria for ECG abnormalities: maximum PR interval \>=300 milliseconds (msec) and maximum increase PR interval increase from baseline (IFB): percent change (Pctchg) \>=25 percent (%) for baseline value of \>200 msec and Pctchg\>=50% for baseline value of \<=200 msec for PR interval, maximum QRS interval \>=140 msec and a maximum IFB: Pctchg\>=50%, maximum QTCF interval (Fridericia's Correction) of 450 msec to \<480 msec, 480 msec to \<500 msec or \>=500 msec and a maximum change of \<=30change\<60 or \>=60 msec from baseline.

Time frame:
Baseline up to Day 30
Reported as:
Number · participants
Number of Participants With Electrocardiogram (ECG) Abnormalities
participantsL-DopaPF-06649751 5 mg + L-DopaPF-06649751 15 mg + L-DopaPF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID)PF-06649751 25 mg + L-Dopa
Number of Participants With Electrocardiogram (ECG) Abnormalities20212
PrimaryNumber of Participants With Clinically Significant Change From Baseline in Physical Examination Findings

Physical examination included examination of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms. Findings were considered to be clinically significant based on investigator's decision.

Time frame:
Baseline up to Day 30
Reported as:
Number · participants
Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings
participantsL-DopaPF-06649751 5 mg + L-DopaPF-06649751 15 mg + L-DopaPF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID)PF-06649751 25 mg + L-Dopa
Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings00000
PrimaryNumber of Participants With Clinically Significant Neurological Examination Abnormality

The complete or full neurological examination included assessment of the cranial nerves; muscle strength, tone, cortical drift, abnormal movements; deep tendon reflexes; sensory exam, coordination, gait and station. Higher cortical and motor function was considered part of the complete neurological exam. Findings were considered abnormal as confirmed by a certified neurologist.

Time frame:
Baseline up to Day 30
Reported as:
Number · participants
Number of Participants With Clinically Significant Neurological Examination Abnormality
participantsL-DopaPF-06649751 5 mg + L-DopaPF-06649751 15 mg + L-DopaPF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID)PF-06649751 25 mg + L-Dopa
Number of Participants With Clinically Significant Neurological Examination Abnormality00001
PrimaryNumber of Participants With Categorical Scores on The Columbia Suicide Severity Rating Scale (C-SSRS)

The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").

Time frame:
Baseline up to Day 30
Reported as:
Number · participants
Number of Participants With Categorical Scores on The Columbia Suicide Severity Rating Scale (C-SSRS)
participantsPF-06649751 5 mg + L-DopaPF-06649751 15 mg + L-DopaPF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID)PF-06649751 25 mg + L-Dopa
Number of Participants With Categorical Scores on The Columbia Suicide Severity Rating Scale (C-SSRS)0000
PrimaryChange From Baseline in Parkinson's Disease Diary For Participants With Motor Fluctuations at Day 13

According to Parkinson's disease diaries of participants "OFF" time was a time period when the medication no longer providing benefit with regard to mobility, slowness, and stiffness and participants experienced relatively poor overall function with worsening of tremor, rigidity, balance, or bradykinesia. "ON" time was a time period when medication was providing benefit with regard to mobility, slowness, and stiffness. "ON" time was classified as associated with or without troublesome dyskinesia (TD) that interfere with activities of daily living and with or without dyskinesia. "OFF" time and "ON" time with TD were generally considered to be "bad time" with regard to motor function, whereas "ON" time without dyskinesia (WD) and with non- troublesome dyskinesia (NTD) were generally considered to be "good time".

Time frame:
Baseline, Day 13
Reported as:
Mean · hour
Change From Baseline in Parkinson's Disease Diary For Participants With Motor Fluctuations at Day 13
hourPF-06649751 5 mg + L-DopaPF-06649751 15 mg + L-DopaPF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID)PF-06649751 25 mg + L-Dopa
Total OFF time: Baseline (n=9,11,6,19)4.42 ± 5.0736.18 ± 3.4336.75 ± 1.7896.05 ± 3.981
Total OFF time: Change at Day 13 (n=9,9,3,9)-0.14 ± 3.310-0.31 ± 4.9761.75 ± 2.646-2.44 ± 6.335
Total ON time: Baseline (n=9,11,6,19)11.92 ± 5.3289.52 ± 3.6658.13 ± 3.48510.96 ± 4.862
Total ON time: Change at Day 13 (n=9,9,3,9)1.86 ± 4.1501.81 ± 6.644-4.25 ± 0.7500.06 ± 6.232
ON time WD: Baseline (n=9, 11, 6, 19)7.58 ± 5.9958.59 ± 2.9964.13 ± 3.7819.14 ± 5.950
ON time WD: Change at Day 13 (n=9, 9, 3, 9)-1.50 ± 4.0811.86 ± 6.519-1.75 ± 3.031-0.78 ± 4.604
ON time with dyskinesia: Baseline (n=9,11,6,19)4.33 ± 5.8510.93 ± 1.9464.00 ± 3.6981.82 ± 3.326
ON time with dyskinesia:Change at Day13(n=9,9,3,9)3.36 ± 5.460-0.06 ± 0.891-2.50 ± 2.4110.83 ± 6.294
ON time with TD: Baseline (n=9, 11, 6, 19)1.56 ± 2.5180.36 ± 0.8760.29 ± 0.5100.43 ± 1.833
ON time with TD: Change at Day 13 (n=9, 9, 3, 9)1.58 ± 2.469-0.14 ± 0.4170.25 ± 0.433-0.67 ± 2.000
Good ON time: Baseline (n=9, 11, 6, 19)10.36 ± 5.0539.16 ± 3.1817.83 ± 3.31910.53 ± 5.165
Good ON time: Change at Day 13 (n=9, 9, 3, 9)0.28 ± 2.8301.94 ± 6.690-4.50 ± 1.1460.72 ± 5.906
Total Awake time: Baseline (n=9, 11, 6, 19)16.33 ± 1.62015.70 ± 1.49514.88 ± 2.60217.01 ± 4.063
Total Awake time: Change at Day 13 (n=9, 9, 3, 9)1.72 ± 1.7481.50 ± 3.267-2.50 ± 2.883-2.39 ± 5.456
Total Asleep time: Baseline (n=9, 11, 6, 19)7.67 ± 1.6208.30 ± 1.4957.92 ± 2.0536.24 ± 2.895
Total Asleep time: Change at Day 13 (n=9, 9, 3, 9)-1.72 ± 1.748-1.50 ± 3.267-0.33 ± 2.6260.44 ± 0.982
PrimaryChange From Baseline in Parkinson's Disease Diary For Participants With Motor Fluctuations at Day 20

According to Parkinson's disease diaries of participants "OFF" time was a time period when the medication no longer providing benefit with regard to mobility, slowness, and stiffness and participants experienced relatively poor overall function with worsening of tremor, rigidity, balance, or bradykinesia. "ON" time was a time period when medication was providing benefit with regard to mobility, slowness, and stiffness. "ON" time was classified as associated with or without troublesome dyskinesia (TD) that interfere with activities of daily living and with or without dyskinesia. "OFF" time and "ON" time with TD were generally considered to be "bad time" with regard to motor function, whereas "ON" time without dyskinesia (WD) and with non- troublesome dyskinesia (NTD) were generally considered to be "good time".

Time frame:
Baseline, Day 20
Reported as:
Mean · hour
Change From Baseline in Parkinson's Disease Diary For Participants With Motor Fluctuations at Day 20
hourPF-06649751 5 mg + L-DopaPF-06649751 15 mg + L-DopaPF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID)PF-06649751 25 mg + L-Dopa
Total OFF time: Change at Day 201.97 ± 3.166-0.19 ± 2.9650.63 ± 4.419-1.94 ± 5.603
Total ON time: Change at Day 20-1.53 ± 3.5560.69 ± 3.739-0.63 ± 3.0050.66 ± 6.518
ON time WD: Change at Day 20-2.61 ± 3.8141.06 ± 3.980-2.13 ± 3.005-0.41 ± 3.659
ON time with dyskinesia: Change at Day 201.08 ± 5.297-0.36 ± 0.7301.50 ± 6.0101.06 ± 8.174
ON time with TD: Change at Day 200.47 ± 1.910-0.08 ± 0.4680.25 ± 0.000-0.66 ± 1.856
Good ON time: Change at Day 20-2.00 ± 2.6130.78 ± 3.768-0.88 ± 3.0051.31 ± 6.088
Total Awake time: Change at Day 200.44 ± 1.1160.50 ± 2.1540.00 ± 1.414-1.28 ± 1.538
Total Asleep time: Change at Day 20-0.44 ± 1.116-0.50 ± 2.1540.00 ± 1.4141.28 ± 1.538
SecondaryMaximum Observed Plasma Concentration (Cmax) of L-Dopa
Time frame:
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of L-Dopa
nanogram per milliliter (ng/mL)L-Dopa
Maximum Observed Plasma Concentration (Cmax) of L-Dopa2817 ± 60
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of L-Dopa
Time frame:
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
Reported as:
Median · hour
Time to Reach Maximum Observed Plasma Concentration (Tmax) of L-Dopa
hourL-Dopa
Time to Reach Maximum Observed Plasma Concentration (Tmax) of L-Dopa0.517 (0.417 to 8.25)
SecondaryApparent Clearance (CL/F) of L-Dopa

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
Reported as:
Geometric mean · liter per hour (L/hr)
Apparent Clearance (CL/F) of L-Dopa
liter per hour (L/hr)L-Dopa
Apparent Clearance (CL/F) of L-Dopa33.57 ± 37
SecondaryTerminal Half-Life (t1/2) of L-Dopa

Terminal half-life is the time measured for the plasma concentration of drug to decrease by one half. It was calculated as dividing the natural logarithm to the base e (Log e)\*2/k el, where k el is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
Reported as:
Mean · hour
Terminal Half-Life (t1/2) of L-Dopa
hourL-Dopa
Terminal Half-Life (t1/2) of L-Dopa1.534 ± 0.23847
SecondaryArea Under the Curve From Time Zero Extrapolated to Infinite Time of L-Dopa

AUC (0 - inf)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf). It is obtained from AUC (0 - t) plus AUC (t - inf).

Time frame:
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Curve From Time Zero Extrapolated to Infinite Time of L-Dopa
nanogram*hour per milliliter (ng*hr/mL)L-Dopa
Area Under the Curve From Time Zero Extrapolated to Infinite Time of L-Dopa6117 ± 57
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration of L-Dopa

Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (C last).

Time frame:
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration of L-Dopa
ng*hr/mLL-Dopa
Area Under the Curve From Time Zero to Last Quantifiable Concentration of L-Dopa6152 ± 56
SecondaryApparent Volume of Distribution (Vz/F) of L-Dopa

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Time frame:
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
Reported as:
Geometric mean · Liter (L)
Apparent Volume of Distribution (Vz/F) of L-Dopa
Liter (L)L-Dopa
Apparent Volume of Distribution (Vz/F) of L-Dopa73.41 ± 41
SecondaryMaximum Observed Plasma Concentration (Cmax) of PF-06649751
Time frame:
Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of PF-06649751
ng/mLPF-06649751 5 mg + L-DopaPF-06649751 15 mg + L-DopaPF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID)PF-06649751 25 mg + L-Dopa
Day 7 (n =9, 9, 5, 14)18.95 ± 5153.69 ± 4131.72 ± 2568.17 ± 23
Day 13 (n =9, 7, 3, 5)79.87 ± 27215.7 ± 48143.6 ± 27309.0 ± 20
Day 22 (n =9, 7, 3, 7)118.5 ± 33325.4 ± 46241.2 ± 26401.6 ± 41
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06649751
Time frame:
Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
Reported as:
Median · hour
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06649751
hourPF-06649751 5 mg + L-DopaPF-06649751 15 mg + L-DopaPF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID)PF-06649751 25 mg + L-Dopa
Day 7 (n =9, 9, 5, 14)1.00 (0.500 to 4.00)2.45 (1.03 to 4.15)2.00 (1.75 to 4.00)3.18 (0.500 to 11.6)
Day 13 (n =9, 7, 3, 1)2.00 (0.833 to 12.0)3.92 (2.03 to 11.8)2.00 (2.00 to 4.00)8.00 (8.00 to 8.00)
Day 22 (n =9, 7, 3, 7)2.00 (1.00 to 4.00)4.00 (2.00 to 12.0)2.02 (2.00 to 4.00)4.03 (1.97 to 8.00)
SecondaryApparent Clearance (CL/F) of PF-06649751

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 22
Reported as:
Geometric mean · L/hr
Apparent Clearance (CL/F) of PF-06649751
L/hrPF-06649751 5 mg + L-DopaPF-06649751 15 mg + L-DopaPF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID)PF-06649751 25 mg + L-Dopa
Apparent Clearance (CL/F) of PF-066497512.377 ± 352.504 ± 613.511 ± 403.483 ± 52
SecondaryArea Under the Curve From Time Zero to End of Dosing Interval of PF-06649751

Area under the concentration curve from time zero to end of dosing interval (AUCtau), where dosing interval was 12 hours.

Time frame:
Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to End of Dosing Interval of PF-06649751
ng*hr/mLPF-06649751 5 mg + L-DopaPF-06649751 15 mg + L-DopaPF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID)PF-06649751 25 mg + L-Dopa
Day 7 (n =9, 9, 5, 14)261.9 ± 30990.8 ± 56530.9 ± 301203 ± 25
Day 13 (n =9, 7, 3, 5)1438 ± 304192 ± 612414 ± 395498 ± 32
Day 22 (n =9, 7, 3, 7)2105 ± 355993 ± 614271 ± 407182 ± 52
SecondaryMinimum Observed Plasma Trough Concentration (Cmin) of PF-06649751
Time frame:
Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
Reported as:
Geometric mean · ng/mL
Minimum Observed Plasma Trough Concentration (Cmin) of PF-06649751
ng/mLPF-06649751 5 mg + L-DopaPF-06649751 15 mg + L-DopaPF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID)PF-06649751 25 mg + L-Dopa
Day 7 (n =9, 9, 5, 14)7.295 ± 3027.97 ± 6614.19 ± 3824.29 ± 36
Day 13 (n =9, 7, 3, 5)35.00 ± 69132.5 ± 7765.19 ± 56162.3 ± 37
Day 22 (n =9, 7, 3, 7)68.14 ± 44197.9 ± 78120.8 ± 68215.1 ± 63
SecondaryRatio of Accumulation for Area Under the Curve From Time Zero to End of Dosing Interval of PF-06649751

Rac was obtained from AUCtau after last dose divided by AUCtau after first dose, where AUC(tau) = Area under the concentration curve from time zero to end of dosing interval (AUCtau), where dosing interval was 12 hours.

Time frame:
Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22

No measurements were reported for this outcome.

Adverse events

Collected over Baseline (Day 1) up to Day 30. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
L-Dopa—0/50 (0%)8/50 (16%)
PF-06649751 5 mg + L-Dopa—0/9 (0%)9/9 (100%)
PF-06649751 15 mg + L-Dopa—0/11 (0%)7/11 (63.6%)
PF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID)—0/6 (0%)5/6 (83.3%)
PF-06649751 25 mg + L-Dopa—1/19 (5.3%)15/19 (78.9%)
Most frequent serious events
Most frequent serious events
EventL-DopaPF-06649751 5 mg + L-DopaPF-06649751 15 mg + L-DopaPF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID)PF-06649751 25 mg + L-Dopa
PalpitationsCardiac disorders0/500/90/110/61/19
Most frequent other events
Showing 10 of 66
Most frequent other events
EventL-DopaPF-06649751 5 mg + L-DopaPF-06649751 15 mg + L-DopaPF-06649751 15 mg + L-Dopa: L-dopa Induced Dyskinesia (LID)PF-06649751 25 mg + L-Dopa
HeadacheNervous system disorders1/506/97/113/68/19
NauseaGastrointestinal disorders4/500/93/112/68/19
Abdominal discomfortGastrointestinal disorders0/500/90/112/61/19
Neck painMusculoskeletal and connective tissue disorders0/501/91/112/61/19
DizzinessNervous system disorders0/500/92/112/65/19
SomnolenceNervous system disorders1/502/90/112/61/19
Abnormal dreamsPsychiatric disorders0/503/92/111/63/19
AnxietyPsychiatric disorders0/501/91/112/61/19
InsomniaPsychiatric disorders3/503/90/110/60/19
NightmarePsychiatric disorders1/501/90/112/62/19

Baseline characteristics

Full analysis set (FAS) included all participants who received at least 1 dose of study medication (L-Dopa or PF-06649751) in Period 1 and/or Period 2.

Age, Continuous
Age, Continuous(years)Overall Study
Mean64.2 ± 6.9
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female19
Male31
08

Study locations

17 sites
  • Orange Coast Memorial Medical Center
    Fountain Valley, California 92708, United States
  • The Parkinson's and Movement Disorder Institute
    Fountain Valley, California 92708, United States
  • Collaborative Neuroscience Network, LLC
    Long Beach, California 90806, United States
  • Rocky Mountain Movement Disorders Center
    Englewood, Colorado 80113, United States
  • Davita Clinical Research Center
    Lakewood, Colorado 80228, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • Compass Research, LLC
    Orlando, Florida 32806, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Massachusetts General Hospital -- FOR DRUG SHIPMENT ONLY
    Boston, Massachusetts 02114, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Quest Research Institute
    Farmington Hills, Michigan 48334, United States
  • PRA International
    Marlton, New Jersey 08053, United States
  • Carolina Phase I Research, LLC
    Raleigh, North Carolina 27612, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Neurology Consultants of Dallas, PA
    Dallas, Texas 75231, United States
  • Walnut Hill Medical Center
    Dallas, Texas 75231, United States
  • Pfizer Clinical Research Unit
    Brussels, B-1070, Belgium
09

References and documents

Publications

  • Sohur US, Gray DL, Duvvuri S, Zhang Y, Thayer K, Feng G. Phase 1 Parkinson's Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated. Neurol Ther. 2018 Dec;7(2):307-319. doi: 10.1007/s40120-018-0114-z. Epub 2018 Oct 25. PubMed 30361858 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2014
First posted
Aug 25, 2014
Start
Oct 2014
Primary completionActual
Mar 2016
CompletionActual
Mar 2016
Results first posted
Mar 27, 2017
Last update
Mar 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02224664
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 25, 2014
Start date
Oct 2014
Primary completion
Mar 2016
Completion
Mar 2016
Results posted
Mar 27, 2017
Last update
Mar 27, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tavapadon

Start the discussion